Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 13 (12) , e70016
Abstract
Objectives: In clinical chimeric antigen receptor (CAR) T cell therapy, one of the strongest correlates of favorable patient responses is lower levels of differentiation in T cells from the peripheral blood mononuclear cell (PBMC) starting material or the CAR T cell product. T cells from older patients are inherently more differentiated, but we hypothesised that specific activation protocols could be used to limit CAR T cell differentiation during manufacturing, particularly in older patients.Methods: We used PBMCs from young (20–30 years old) and older (60+ years old) healthy donors to generate CAR T cells using two activation protocols: soluble anti‐(α) CD3 monoclonal antibody (mAb) vs immune complexes of αCD3 and αCD28 mAbs. Products were assessed for yield, function and differentiation, which was used as a measure of CAR T cell quality. T cells in PBMCs were assessed for CD28 expression and correlative analyses were performed.Results: Older samples generated fewer, more differentiated CAR T cells than young samples, and the αCD3/CD28 mAb protocol exacerbated this, further reducing yield and quality. CD28 expression by T cells correlated with CAR T cell differentiation, but T cell differentiation in PBMC starting material was a stronger correlate of CAR T cell differentiation.Conclusions: Choice of activation protocol can substantially impact on the yield and quality of CAR T cells during manufacturing. This is a key consideration for older patients whose samples already generate a poorer yield and lower quality of CAR T cells.Keywords
Funding Information
- Victorian Cancer Agency
- National Health and Medical Research Council
- RMIT University
- Rebecca L. Cooper Medical Research Foundation
- National Breast Cancer Foundation
This publication has 42 references indexed in Scilit:
- National Serosurvey of Cytomegalovirus in AustraliaClinical and Vaccine Immunology, 2006
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsJournal of Experimental Medicine, 2005
- Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumorsBlood, 2002
- Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infectionsNature Medicine, 2002
- CD28 as a Molecular Amplifier Extending TCR Ligation and Signaling CapabilitiesImmunity, 2001
- Retroviral-Mediated Gene Transfer in Primary Murine and Human T-LymphocytesMolecular Biotechnology, 2000
- Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response.Journal of Clinical Investigation, 1997
- Expansion of cytotoxic CD8+ CD28− T cells in healthy ageing people, including centenariansImmunology, 1996
- Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthBritish Journal of Cancer, 1993
- Activation of T cells by cross‐linking an anti‐CD3 antibody with a second anti‐T cell antibody: mechanism and subset‐specific activationEuropean Journal of Immunology, 1987